Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Mar-24 4:19 PM View:  | Papadopoulos Stelios Director | Regulus Therapeutics Inc. (RGLS) | 14-Mar-24 | Grant | 250,000 | $1.60 | $400,000.00 | 34% 728.39K to 978.39K | |
| 18-Jan-24 8:24 PM View: | Calsada Crispina Chief Financial Officer | Regulus Therapeutics Inc. (RGLS) | 18-Jan-24 | Private Sale | 5,468 | $1.19 | $6,510.20 | (49%) 11.25K to 5.78K | |
| 18-Jan-24 8:22 PM View: | Hagan Joseph P Chief Executive Officer Director | Regulus Therapeutics Inc. (RGLS) | 18-Jan-24 | Private Sale (Planned) | 14,580 | $1.19 | $17,358.90 | (20%) 71.69K to 57.11K | |
| 18-Jan-24 8:23 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 18-Jan-24 | Private Sale (Planned) | 5,468 | $1.19 | $6,510.20 | (35%) 15.52K to 10.06K | |
| 17-Jan-24 5:16 PM View: | Hagan Joseph P Chief Executive Officer Director | Regulus Therapeutics Inc. (RGLS) | 12-Jan-24 | Grant | 30,000 | -- | -- | 72% 41.69K to 71.69K | |
| 17-Jan-24 5:04 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 12-Jan-24 | Grant | 11,250 | -- | -- | 263% 4.27K to 15.52K | |
| 17-Jan-24 5:08 PM View: | Calsada Crispina Chief Financial Officer | Regulus Therapeutics Inc. (RGLS) | 12-Jan-24 | Grant | 11,250 | -- | -- | 100% 0 to 11.25K | |
| 14-Apr-23 4:39 PM View: | Papadopoulos Stelios Director | Regulus Therapeutics Inc. (RGLS) | 13-Apr-23 | Grant | 222,198 | $0.90 | $200,000.00 | 44% 506.19K to 728.39K | |
| 01-Mar-22 10:00 PM View: | Drygin Denis Chief Scientific Officer | Regulus Therapeutics Inc. (RGLS) | 01-Mar-22 | Private Purchase | 76,686 | $0.23 | $17,637.80 | 329% 23.31K to 100.0K | |
| 07-Feb-22 5:09 PM View: | Drygin Denis Chief Scientific Officer | Regulus Therapeutics Inc. (RGLS) | 04-Feb-22 | Private Purchase | 23,314 | $0.23 | $5,362.22 | 100% 0 to 23.31K | |
| 26-Jan-22 4:13 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 26-Jan-22 | Private Purchase | 100,000 | $0.22 | $21,520.00 | 32% 317.01K to 417.01K | |
| 01-Dec-21 4:12 PM View: | Papadopoulos Stelios Director | Regulus Therapeutics Inc. (RGLS) | 30-Nov-21 | Grant | 2,222,220 | $0.36 | $800,000.00 | 78% 2.84M to 5.06M | |
| 17-May-21 7:12 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 17-May-21 | Market Sale (Planned) | 860 | $0.89 | $765.40 | (2%) 42.61K to 41.75K | 1% |
| 17-May-21 7:13 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 17-May-21 | Market Sale (Planned) | 4,186 | $0.89 | $3,725.54 | (1%) 320.48K to 316.29K | (2%) |
| 16-Apr-21 10:00 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 14-Apr-21 | Conversion | 75,850 | -- | -- | 31% 244.63K to 320.48K | |
| 17-Feb-21 5:23 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 16-Feb-21 | Market Sale (Planned) | 4,144 | $1.72 | $7,127.68 | (< 1%) 489.9K to 485.76K | (13%) |
| 17-Feb-21 5:23 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 16-Feb-21 | Market Sale (Planned) | 828 | $1.72 | $1,424.16 | (2%) 43.44K to 42.61K | (13%) |
| 07-Dec-20 5:10 PM View: | Florence Anthony A. Jr. 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:13 PM View: | Sonsini Peter W. 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:09 PM View: | Behbahani Ali 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:06 PM View: | Growth Equity Opportunities... 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:08 PM View: | Baskett Forest 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:12 PM View: | Makower Joshua 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:14 PM View: | Walker Paul Edward 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:12 PM View: | Sandell Scott D 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 4:21 PM View: | Papadopoulos Stelios Director | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Grant | 793,528 | $0.63 | $500,002.00 | 67% 1.19M to 1.99M | |
| 07-Dec-20 4:22 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Grant | 39,680 | $0.63 | $25,002.40 | 21% 185.99K to 225.67K | |
| 07-Dec-20 5:11 PM View: | Makhzoumi Mohamad 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 07-Dec-20 5:10 PM View: | Chang Carmen 10% Owner | Regulus Therapeutics Inc. (RGLS) | 04-Dec-20 | Private Purchase Duplicate | 4,398,600 | $0.62 | $2,735,930.00 | 214% 2.05M to 6.45M | |
| 18-Nov-20 4:10 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 16-Nov-20 | Market Sale (Planned) | 876 | $0.52 | $456.48 | (3%) 26.64K to 25.76K | (179%) |
| 18-Nov-20 4:09 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 16-Nov-20 | Market Sale (Planned) | 6,094 | $0.52 | $3,175.58 | (3%) 222.09K to 215.99K | (179%) |
| 17-Aug-20 8:21 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 14-Aug-20 | Market Sale (Planned) | 872 | $0.61 | $527.56 | (3%) 27.51K to 26.64K | (154%) |
| 17-Aug-20 8:22 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 14-Aug-20 | Market Sale (Planned) | 4,245 | $0.60 | $2,567.80 | (2%) 226.33K to 222.09K | (154%) |
| 18-May-20 4:28 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 15-May-20 | Market Sale (Planned) | 4,426 | $0.63 | $2,773.77 | (2%) 230.76K to 226.33K | (147%) |
| 18-May-20 4:27 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 15-May-20 | Market Sale (Planned) | 909 | $0.63 | $569.76 | (3%) 28.42K to 27.51K | (147%) |
| 19-Feb-20 6:08 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 18-Feb-20 | Market Sale (Planned) | 888 | $0.83 | $737.48 | (3%) 29.31K to 28.42K | (92%) |
| 19-Feb-20 6:09 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 18-Feb-20 | Market Sale (Planned) | 4,324 | $0.83 | $3,590.65 | (2%) 235.08K to 230.76K | (92%) |
| 04-Feb-20 4:59 PM View: | Papadopoulos Stelios Director | Regulus Therapeutics Inc. (RGLS) | 03-Feb-20 | Conversion | 846,320 | -- | -- | 71% 1.19M to 2.04M | |
| 04-Feb-20 5:05 PM View: | Rastetter William H Director | Regulus Therapeutics Inc. (RGLS) | 03-Feb-20 | Conversion | 225,940 | -- | -- | 137% 164.64K to 390.58K | |
| 03-Jan-20 4:06 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 02-Jan-20 | Market Sale (Planned) | 2,239 | $0.97 | $2,164.44 | (7%) 31.55K to 29.31K | (65%) |
| 03-Jan-20 4:07 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 02-Jan-20 | Market Sale (Planned) | 8,345 | $0.97 | $8,067.11 | (3%) 243.43K to 235.08K | (65%) |
| 15-Nov-19 5:36 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 14-Nov-19 | Market Sale (Planned) | 5,838 | $0.64 | $3,736.32 | (2%) 249.27K to 243.43K | (146%) |
| 15-Nov-19 5:37 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 14-Nov-19 | Market Sale (Planned) | 833 | $0.64 | $533.12 | (3%) 32.38K to 31.55K | (146%) |
| 02-Oct-19 6:50 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 01-Oct-19 | Market Sale (Planned) | 2,346 | $0.68 | $1,601.61 | (7%) 34.73K to 32.38K | (128%) |
| 02-Oct-19 6:17 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 01-Oct-19 | Market Sale (Planned) | 8,743 | $0.68 | $5,968.85 | (3%) 258.01K to 249.27K | (128%) |
| 16-Aug-19 4:17 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 15-Aug-19 | Market Sale (Planned) | 4,375 | $0.55 | $2,408.88 | (2%) 262.38K to 258.01K | (184%) |
| 16-Aug-19 4:16 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 15-Aug-19 | Market Sale (Planned) | 899 | $0.55 | $494.99 | (3%) 35.62K to 34.73K | (184%) |
| 02-Jul-19 5:42 PM View: | Hagan Joseph P President and CEO Director | Regulus Therapeutics Inc. (RGLS) | 01-Jul-19 | Market Sale (Planned) | 5,783 | $1.31 | $7,584.40 | (2%) 268.17K to 262.38K | (18%) |
| 02-Jul-19 5:41 PM View: | Chevallard Daniel R. Chief Financial Officer | Regulus Therapeutics Inc. (RGLS) | 01-Jul-19 | Market Sale (Planned) | 2,669 | $1.31 | $3,500.39 | (3%) 80.54K to 77.87K | (18%) |
| 02-Jul-19 5:42 PM View: | Aker Christopher Ray Sr. VP & General Counsel | Regulus Therapeutics Inc. (RGLS) | 01-Jul-19 | Market Sale (Planned) | 2,225 | $1.31 | $2,918.09 | (6%) 37.85K to 35.62K | (18%) |
